LivaNova layoffs, on the record
Every job cut, severance charge and restructuring LivaNova reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 2,900 to approximately 3,300.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2024 | approximately 2,900 | — |
| 10-K for 2025 | approximately 3,300 | As of December 31, 2025 |
Job cuts, severance and restructuring
Our summaryThe board approved a 2024 Restructuring Plan to focus the company on its Cardiopulmonary and Neuromodulation segments.
Word for word“On January 5, 2024, the Board of Directors of LivaNova PLC approved the 2024 Restructuring Plan to enhance the Company’s focus on its core Cardiopulmonary and Neuromodulation segments.” 10-K for 2023
Our summaryThe company plans to discontinue LifeSPARC and Hemolung operations as part of winding down the ACS segment.
Word for word“Operations for other ACS products, including LifeSPARC and Hemolung systems, will be discontinued by the end of 2024.” 10-K for 2023
Our summaryThe company started a 2024 restructuring plan to sharpen its focus on its core Cardiopulmonary and Neuromodulation segments.
Word for word“2024 Restructuring Plan A plan, initiated during the first quarter of 2024, to enhance LivaNova’s focus on its core Cardiopulmonary and Neuromodulation segments” 10-K for 2025
Our summaryRestructuring expense fell by $13.5 million in 2025 compared with 2024, and the company points readers to the restructuring note for more detail.
Word for word“The decrease was primarily due to a decrease in the amount recorded for the litigation provision related to LivaNova’s 3T Heater-Cooler device of $15.3 million, as well as a decrease in restructuring expense of $13.5 million.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $37.4 million | — |
| 2017-12-31 | $17.1 million | $33.1 million |
| 2018-12-31 | $15.9 million | $9.8 million |
| 2019-12-31 | $0 | $20 million |
| 2020-12-31 | $0 | $6.8 million |
| 2021-12-31 | $9.7 million | $15.2 million |
| 2022-12-31 | $6.6 million | $5.4 million |
| 2023-12-31 | $956,000 | $2.1 million |
| 2024-12-31 | $13.4 million | $11.7 million |
| 2025-12-31 | −$177,000 | $2.4 million |
LivaNova filed 3 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from LivaNova’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.